Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation
- PMID: 10096098
- DOI: 10.1177/135245859900500104
Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation
Abstract
Experimental autoimmune encephalomyelitis (EAE) is an inducible autoimmune disease widely used as a model of the acute/relapsing stage of multiple sclerosis. We have previously shown that treatment of EAE-mice with high doses of cyclophosphamide (CY) (350 mg kg), followed by syngeneic bone marrow transplantation (SBMT), completely abrogates the clinical paralytic signs and even prevents the appearance of new relapses in the chronic-relapsing model of the disease. In the present study we examined whether this treatment protocol induces long term tolerance and whether this tolerance is antigen-specific. EAE was induced by immunization with spinal cord homogenate (MSCH) in complete Freund's adjuvant (CFA). The treatment with CY and SBMT was performed on day 6 post immunization. Treated and untreated mice were rechallenged with MSCH, or a non-relevant antigen (OVA) in CFA at various stages after the first paralytic attack. In contrast to previous data showing that animals recovering from acute EAE are usually refractory to re-induction of the disease, repeated injections of MSCH at different sites from the initial immunization, followed by i.v. injection of inactivated Bordetella bacteria, 2, 4 and 6 months after the initial EAE-induction, caused a severe and usually lethal relapse in all the untreated, control animals. Mice treated with CY and SBMT were resistant to all rechallenges with the same encephalitogenic inoculum. Following the second rechallenge, peripheral lymph node cells were examined in vitro for their proliferative responses to myelin antigens or to OVA. Lymphocytes obtained from CY+SBMT treated mice did not proliferate in vitro in response to myelin basic protein (MBP), but proliferated against OVA, when immunized with this antigen, after SBMT. Adoptive transfer of lymphocytes from tolerant mice to naive recipients did not transfer resistance to EAE-induction. Our results indicate that high doses of CY, followed by SBMT, induce long term antigen-specific tolerance presumably by a mechanism of clonal deletion or anergy.
Similar articles
-
Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation.J Immunol. 1992 Mar 15;148(6):1693-8. J Immunol. 1992. PMID: 1541813
-
Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation.J Neuroimmunol. 1992 Aug;39(3):201-10. doi: 10.1016/0165-5728(92)90254-i. J Neuroimmunol. 1992. PMID: 1644896
-
Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.J Clin Invest. 1993 Aug;92(2):765-72. doi: 10.1172/JCI116648. J Clin Invest. 1993. PMID: 7688762 Free PMC article.
-
Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures.J Neurol Sci. 2004 Aug 15;223(1):59-64. doi: 10.1016/j.jns.2004.04.021. J Neurol Sci. 2004. PMID: 15261562 Review.
-
Antigen-specific tolerance as a therapy for experimental autoimmune encephalomyelitis.Int Rev Immunol. 1992;9(3):203-22. doi: 10.3109/08830189209061791. Int Rev Immunol. 1992. PMID: 1285061 Review.
Cited by
-
Aggressive multiple sclerosis-is there a role for stem cell transplantation?J Neurol. 2005 Sep;252 Suppl 3:iii34-iii37. doi: 10.1007/s00415-005-2015-1. J Neurol. 2005. PMID: 16170499 Review.
-
Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?Int J Hematol. 2002 Aug;76 Suppl 1:226-47. doi: 10.1007/BF03165251. Int J Hematol. 2002. PMID: 12430858 Review.
-
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.Blood. 2003 Oct 1;102(7):2364-72. doi: 10.1182/blood-2002-12-3908. Epub 2003 May 22. Blood. 2003. PMID: 12763935 Free PMC article. Clinical Trial.
-
Immunologic therapy for secondary and primary progressive multiple sclerosis.Curr Neurol Neurosci Rep. 2001 May;1(3):286-93. doi: 10.1007/s11910-001-0032-8. Curr Neurol Neurosci Rep. 2001. PMID: 11898531 Review.
-
Advances in hematopoietic stem cell transplantation for autoimmune diseases.Heliyon. 2024 Oct 11;10(20):e39302. doi: 10.1016/j.heliyon.2024.e39302. eCollection 2024 Oct 30. Heliyon. 2024. PMID: 39492896 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous